A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database

Documenti analoghi

• Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
  di: Pooja Gokhale, et al.
  Pubblicazione: (2026)
• Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
  di: Shaimaa Elshafie, et al.
  Pubblicazione: (2024)
• A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
  di: Yajing Xu, et al.
  Pubblicazione: (2025)
• Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
  di: Wenke Li, et al.
  Pubblicazione: (2025)
• Current Knowledge of Immune Checkpoint Inhibitor‐Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management
  di: Youran Dai, et al.
  Pubblicazione: (2026)